Localized delivery of low-density lipoprotein docosahexaenoic acid nanoparticles to the rat brain using focused ultrasound

Biomaterials

Volumn 83, Issue , 2016, Pages 257-268

  Mulik, Rohit S ^a   Bing, Chenchen ^a   Ladouceur Wodzak, Michelle ^a   Munaweera, Imalka ^a   Chopra, Rajiv ^a   Corbin, Ian R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bloodbrain barrier; Brain; Focused ultrasound; Lipoprotein; Nanoparticle; Omega fatty acid

Indexed keywords

BRAIN; FATTY ACIDS; FLUORESCENCE; LIPOPROTEINS; RATS; TISSUE; ULTRASONICS; UNSATURATED FATTY ACIDS;

BLOOD-BRAIN BARRIER; DOCOSAHEXAENOIC ACID; FLUORESCENCE SIGNALS; FLUORESCENT IMAGING; FOCUSED ULTRASOUND; HISTOLOGICAL EVALUATION; LOW DENSITY LIPOPROTEINS; STRONG LOCALIZATIONS;

NANOPARTICLES;

ARGINYLGLYCYLASPARTIC ACID; ELASTIN; 1,1'-DIOCTADECYL-3,3,3',3'-TETRAMETHYLINDOTRICARBOCYANINE; CARBOCYANINE; DOCOSAHEXAENOIC ACID; LOW DENSITY LIPOPROTEIN; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMINERALIZATION; BONE REGENERATION; CELL ADHESION; CHEMICAL MODIFICATION; CONTROLLED STUDY; CROSS LINKING; FEMALE; FEMUR; FILM; HUMAN; HUMAN CELL; MATERIAL COATING; NONHUMAN; ORTHOPEDIC IMPLANT; PRIORITY JOURNAL; PROTEIN ENGINEERING; RAT; SIGNAL TRANSDUCTION; TIBIA; TOOTH IMPLANT; ANIMAL; BLOOD BRAIN BARRIER; BRAIN; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; METABOLOME; PATHOLOGY; REPRODUCIBILITY; SPRAGUE DAWLEY RAT; STEREOTACTIC PROCEDURE; ULTRASOUND; ULTRASTRUCTURE;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CARBOCYANINES; DOCOSAHEXAENOIC ACIDS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIPOPROTEINS, LDL; METABOLOME; NANOPARTICLES; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; STEREOTAXIC TECHNIQUES; ULTRASONICS;

EID: 84958059628     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.01.021     Document Type: Article

References (72)

1. Pardridge W.M. Drug transport across the blood-brain barrier. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 2012, 32:1959-1972.
2. Rubin L.L., Staddon J.M. The cell biology of the blood-brain barrier. Annu. Rev. Neurosci. 1999, 22:11-28.
3. Stewart P.A., Hayakawa E.M. Interendothelial junctional changes underlie the developmental 'tightening' of the blood-brain barrier. Brain Res. 1987, 429:271-281.
4. Wolburg H., Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vasc. Pharmacol. 2002, 38:323-337.
5. Pardridge W.M. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Interv. 2003, 3:90-105. 51.
6. Cosolo W.C., Martinello P., Louis W.J., Christophidis N. Blood-brain barrier disruption using mannitol: time course and electron microscopy studies. Am. J. Physiol. 1989, 256:R443-R447.
7. Zou L.-L., Ma J.-L., Wang T., Yang T.-B., Liu C.-B. Cell-penetrating peptide-mediated therapeutic molecule delivery into the central nervous system. Curr. Neuropharmacol. 2013, 11:197-208.
8. Bobo R.H., Laske D.W., Akbasak A., Morrison P.F., Dedrick R.L., Oldfield E.H. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. 1994, 91:2076-2080.
9. Fresta M., Puglisi G. Survival rate improvement in a rat ischemia model by long circulating liposomes containing cytidine-5I-diphosphate choline. Life Sci. 1997, 61:1227-1235.
10. Korkusuz H., Ulbrich K., Welzel K., Koeberle V., Watcharin W., Bahr U., et al. Transferrin-coated gadolinium nanoparticles as MRI contrast agent. Mol. imaging Biol. MIB Off. Publ. Acad. Mol. Imaging 2013, 15:148-154.
11. Kreuter J. Influence of chronobiology on the nanoparticle-mediated drug uptake into the brain. Pharmaceutics 2015, 7:3-9.
12. Cosco D., Di Marzio L., Marianecci C., Trapasso E., Paolino D., Celia C., et al. Colloidal supramolecular aggregates for therapeutic application in neuromedicine. Curr. Med. Chem. 2014, 21:4132-4153.
13. Hynynen K., McDannold N., Vykhodtseva N., Jolesz F.A. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 2001, 220:640-646.
14. Sheikov N., McDannold N., Vykhodtseva N., Jolesz F., Hynynen K. Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med. Biol. 2004, 30:979-989.
15. Marty B., Larrat B., Van Landeghem M., Robic C., Robert P., Port M., et al. Dynamic study of blood-brain barrier closure after its disruption using ultrasound: a quantitative analysis. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 2012, 32:1948-1958.
16. Cho E.E., Drazic J., Ganguly M., Stefanovic B., Hynynen K. Two-photon fluorescence microscopy study of cerebrovascular dynamics in ultrasound-induced blood-brain barrier opening. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 2011, 31:1852-1862.
17. Park J., Zhang Y., Vykhodtseva N., Jolesz F.A., McDannold N.J. The kinetics of blood brain barrier permeability and targeted doxorubicin delivery into brain induced by focused ultrasound. J. Control Release 2012, 162:134-142.
18. Hynynen K., McDannold N., Vykhodtseva N., Jolesz F.A. Non-invasive opening of BBB by focused ultrasound. Acta Neurochir. Suppl. 2003, 86:555-558.
19. Chen H., Konofagou E.E. The size of blood-brain barrier opening induced by focused ultrasound is dictated by the acoustic pressure. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 2014, 34:1197-1204.
20. De Jong W.H., Borm P.J.A. Drug delivery and nanoparticles: applications and hazards. Int. J. Nanomed. 2008, 3:133-149.
21. Palombo M., Deshmukh M., Myers D., Gao J., Szekely Z., Sinko P.J. Pharmaceutical and toxicological properties of engineered nanomaterials for drug delivery. Annu. Rev. Pharmacol. Toxicol. 2014, 54:581-598.
22. Masserini M. Nanoparticles for brain drug delivery. ISRN Biochem. 2013, 2013:18.
23. Corbin I.R., Li H., Chen J., Lund-Katz S., Zhou R., Glickson J.D., et al. Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. Neoplasia 2006, 8:488-498.
24. Duivenvoorden R., Tang J., Cormode D.P., Mieszawska A.J., Izquierdo-Garcia D., Ozcan C., et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat. Commun. 2014, 5.
25. Ng K.K., Lovell J.F., Zheng G. Lipoprotein-inspired nanoparticles for cancer theranostics. Acc. Chem. Res. 2011, 44:1105-1113.
26. Allijn I.E., Leong W., Tang J., Gianella A., Mieszawska A.J., Fay F., et al. Gold nanocrystal labeling allows low-density lipoprotein imaging from the subcellular to macroscopic level. ACS Nano 2013, 7:9761-9770.
27. Bing C., Ladouceur-Wodzak M., Wanner C.R., Shelton J.M., Richardson J.A., Chopra R. Trans-cranial opening of the blood-brain barrier in targeted regions using a stereotaxic brain atlas and focused ultrasound energy. J. Ther. Ultrasound 2014, 2:13.
28. Lund-Katz S., Laplaud P.M., Phillips M.C., Chapman M.J. Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction. Biochemistry 1998, 37:12867-12874.
29. Reynolds L., Mulik R.S., Wen X., Dilip A., Corbin I.R. Low-density lipoprotein-mediated delivery of docosahexaenoic acid selectively kills murine liver cancer cells. Nanomedicine UK 2014, 1-19.
30. Li H., Zhang Z., Blessington D., Nelson D.S., Zhou R., Lund-Katz S., et al. Carbocyanine labeled LDL for optical imaging of tumors. Acad. Radiol. 2004, 11:669-677.
31. Stewart J.C. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 1980, 104:10-14.
32. Mehta A., Oeser A.M., Carlson M.G. Rapid quantitation of free fatty acids in human plasma by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 1998, 719:9-23.
33. Zhang L., Tong H., Garewal M., Ren G. Optimized negative-staining electron microscopy for lipoprotein studies. Biochim. Biophys. Acta 2013, 1830:2150-2159.
34. O'Reilly MA, Muller A, Hynynen K. Ultrasound Insertion Loss of Rat Parietal Bone Appears to Be Proportional to Animal Mass at Submegahertz Frequencies. Ultrasound in Medicine and Biology.37:1930-7.
35. Aslan M., Ozcan F., Aslan I., Yucel G. LC-MS/MS analysis of plasma polyunsaturated fatty acids in type 2 diabetic patients after insulin analog initiation therapy. Lipids Health Dis. 2013, 12:169.
36. Zhao Z., Xu Y. An extremely simple method for extraction of lysophospholipids and phospholipids from blood samples. J. Lipid Res. 2010, 51:652-659.
37. Erdahl W.L., Krebsbach R.J., Pfeiffer D.R. A comparison of phospholipid degradation by oxidation and hydrolysis during the mitochondrial permeability transition. Arch. Biochem. Biophys. 1991, 285:252-260.
38. Aggerbeck L.P., Kezdy F.J., Scanu A.M. Enzymatic probes of lipoprotein structure. Hydrolysis of human serum low density lipoprotein-by phospholipase A2. J. Biol. Chem. 1976, 251:3823-3830.
39. Krieger M., McPhaul M.J., Goldstein J.L., Brown M.S. Replacement of neutral lipids of low density lipoprotein with esters of long chain unsaturated fatty acids. J. Biol. Chem. 1979, 254:3845-3853.
40. Shen B.W., Scanu A.M., Kezdy F.J. Structure of human serum lipoproteins inferred from compositional analysis. Proc. Natl. Acad. Sci. U. S. A. 1977, 74:837-841.
41. Choi J.J., Wang S., Tung Y.S., Morrison B., Konofagou E.E. Molecules of various pharmacologically-relevant sizes can cross the ultrasound-induced blood-brain barrier opening in vivo. Ultrasound Med. Biol. 2010, 36:58-67.
42. Panzenboeck U., Balazs Z., Sovic A., Hrzenjak A., Levak-Frank S., Wintersperger A., et al. ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells. J. Biol. Chem. 2002, 277:42781-42789.
43. Dehouck B., Fenart L., Dehouck M.P., Pierce A., Torpier G., Cecchelli R. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 1997, 138:877-889.
44. Spady D.K., Huettinger M., Bilheimer D.W., Dietschy J.M. Role of receptor-independent low density lipoprotein transport in the maintenance of tissue cholesterol balance in the normal and WHHL rabbit. J. Lipid Res. 1987, 28:32-41.
45. Osono Y., Woollett L.A., Herz J., Dietschy J.M. Role of the low density lipoprotein receptor in the flux of cholesterol through the plasma and across the tissues of the mouse. J. Clin. Investig. 1995, 95:1124-1132.
46. Dietschy J.M., Turley S.D. Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 2004, 45:1375-1397.
47. Spady D.K., Bilheimer D.W., Dietschy J.M. Rates of receptor-dependent and -independent low density lipoprotein uptake in the hamster. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:3499-3503.
48. Goppert T.M., Muller R.H. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J. Drug Target 2005, 13:179-187.
49. Kreuter J., Hekmatara T., Dreis S., Vogel T., Gelperina S., Langer K. Covalent attachment of apolipoprotein A-and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J. Control Release 2007, 118:54-58.
50. Lemke A., Kiderlen A.F., Petri B., Kayser O. Delivery of amphotericin B nanosuspensions to the brain and determination of activity against Balamuthia mandrillaris amebas. Nanomedicine UK 2010, 6:597-603.
51. Herz J., Beffert U. Apolipoprotein E receptors: linking brain development and Alzheimer's disease. Nat. Rev. Neurosci. 2000, 1:51-58.
52. Jung-Testas I., Weintraub H., Dupuis D., Eychenne B., Baulieu E.E., Robel P. Low density lipoprotein-receptors in primary cultures of rat glial cells. J. Steroid Biochem. Mol. Biol. 1992, 42:597-605.
53. Bazinet R.P., Laye S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat. Rev. Neurosci. 2014, 15:771-785.
54. Domenichiello A.F., Chen C.T., Trepanier M.O., Stavro P.M., Bazinet R.P. Whole body synthesis rates of DHA from alpha-linolenic acid are greater than brain DHA accretion and uptake rates in adult rats. J. Lipid Res. 2014, 55:62-74.
55. Crawford M.A., Bloom M., Broadhurst C.L., Schmidt W.F., Cunnane S.C., Galli C., et al. Evidence for the unique function of docosahexaenoic acid during the evolution of the modern hominid brain. Lipids 1999, 34(Suppl.):S39-S47.
56. Singh M. Essential fatty acids, DHA and human brain. Indian J. Pediatr. 2005, 72:239-242.
57. Hong S., Gronert K., Devchand P.R., Moussignac R.L., Serhan C.N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 2003, 278:14677-14687.
58. Serhan C.N., Brain S.D., Buckley C.D., Gilroy D.W., Haslett C., O'Neill L.A., et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 2007, 21:325-332.
59. Serhan C.N. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 2007, 25:101-137.
60. Tassoni D., Kaur G., Weisinger R.S., Sinclair A.J. The role of eicosanoids in the brain. Asia Pac. J. Clin. Nutr. 2008, 17(Suppl 1):220-228.
61. Niemoller T.D., Bazan N.G. Docosahexaenoic acid neurolipidomics. Prostagl. Other Lipid Mediat. 2010, 91:85-89.
62. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 1991, 11:81-128.
63. Dyall S.C., Michael-Titus A.T. Neurological benefits of omega-fatty acids. Neuromolecular Med. 2008, 10:219-235.
64. Rapoport S.I., Rao J.S., Igarashi M. Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver. Prostagl. Leukot. Essent. Fat. Acids 2007, 77:251-261.
65. Barberger-Gateau P., Letenneur L., Deschamps V., Peres K., Dartigues J.F., Renaud S. Fish, meat, and risk of dementia: cohort study. BMJ 2002, 325:932-933.
66. Orr S.K., Palumbo S., Bosetti F., Mount H.T., Kang J.X., Greenwood C.E., et al. Unesterified docosahexaenoic acid is protective in neuroinflammation. J. Neurochem. 2013, 127:378-393.
67. Trepanier M.O., Taha A.Y., Mantha R.L., Ciobanu F.A., Zeng Q.H., Tchkhartichvili G.M., et al. Increases in seizure latencies induced by subcutaneous docosahexaenoic acid are lost at higher doses. Epilepsy Res. 2012, 99:225-232.
68. Bazan N.G., Molina M.F., Gordon W.C. Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. Annu. Rev. Nutr. 2011, 31:321-351.
69. Gleissman H., Yang R., Martinod K., Lindskog M., Serhan C.N., Johnsen J.I., et al. Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates. FASEB J. 2010, 24:906-915.
70. Lindskog M., Gleissman H., Ponthan F., Castro J., Kogner P., Johnsen J.I. Neuroblastoma cell death in response to docosahexaenoic acid: sensitization to chemotherapy and arsenic-induced oxidative stress. Int. J. Cancer 2006, 118:2584-2593.
71. Downs M.E., Buch A., Sierra C., Karakatsani M.E., Chen S., Konofagou E.E., et al. Long-term safety of repeated blood-brain Barrier opening via focused ultrasound with microbubbles in non-human primates performing a cognitive task. PLoS One 2015, 10:e0125911.
72. Belayev L., Marcheselli V.L., Khoutorova L., Rodriguez de Turco E.B., Busto R., Ginsberg M.D., et al. Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke J. Cereb. Circ. 2005, 36:118-123.